NCT00167167

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-derived Lymphocytes

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: All
• Age: 1 Year – 60 Years
• Healthy volunteers: Not accepted

Summary

In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.

Detailed description

We will collect immune cells or lymphocytes from the donor's blood using a cell separator. The blood lymphocytes will be given to the subjects through a catheter. If the subjects have no complications of the first course of infusions, we may decide to give them "lymphocytes" aa second time while subjects are in remission in an attempt to prevent their disease from relapsing. A bone marrow test will be taken prior to infusion of lymphocytes as part of the clinical evaluation to receive this treatment. After lymphocyte infusions, a bone marrow will be examined about every three months for the first year to monitor progress from this therapy.

Conditions

• Leukemia, Myeloid, Chronic
• AML
• MDS
• Leukemia, Lymphocytic, Acute

Interventions

Type	Name	Description
PROCEDURE	Donor Lymphocyte Infusion	Certain immune cells in your donor's blood called "lymphocytes" have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's "lymphocytes" in the hope of activating the recipient's immune system to attack cancer.

Timeline

• Start date: 1995-12-01
• Primary completion: 2006-01-01
• Completion: 2006-01-01
• First posted: 2005-09-14
• Last updated: 2017-11-29

Locations

1 site across 1 country: United States